1. Home
  2. WBX vs DSGN Comparison

WBX vs DSGN Comparison

Compare WBX & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wallbox N.V.

WBX

Wallbox N.V.

N/A

Current Price

$3.05

Market Cap

118.0M

ML Signal

N/A

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

N/A

Current Price

$8.76

Market Cap

528.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WBX
DSGN
Founded
2015
2017
Country
Spain
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
118.0M
528.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
WBX
DSGN
Price
$3.05
$8.76
Analyst Decision
Buy
Buy
Analyst Count
4
2
Target Price
$9.00
$13.50
AVG Volume (30 Days)
27.2K
298.9K
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$174,593,453.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$33.37
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.85
$2.60
52 Week High
$14.40
$10.31

Technical Indicators

Market Signals
Indicator
WBX
DSGN
Relative Strength Index (RSI) 36.31 51.79
Support Level $2.88 $9.00
Resistance Level $3.36 $9.67
Average True Range (ATR) 0.27 0.65
MACD 0.04 -0.12
Stochastic Oscillator 13.77 15.64

Price Performance

Historical Comparison
WBX
DSGN

About WBX Wallbox N.V.

Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: